What is the latest domestic price of Afatinib in 2025?

Afatinib is an oral second-generation EGFR-TKI targeted drug, mainly used to treat patients with non-small cell lung cancer with EGFR gene mutations. The drug has been officially launched in China and has been included in the national medical insurance directory, allowing more patients to obtain treatment at a relatively low price. However, due to differences in medical insurance policies, hospital levels and supply conditions in different regions, the specific reimbursement ratio and out-of-pocket amount of afatinib may be different. It is recommended that patients go to local tertiary A hospitals or medical insurance designated pharmacies for consultation and confirmation.

Under the premise of medical insurance reimbursement, the cost of purchasing afatinib for domestic patients is relatively reasonable. According to public information in some areas, after being reimbursed by medical insurance, the actual out-of-pocket amount a patient pays for each box of medicine may only range from more than one thousand to more than two thousand yuan. The common specifications of this medicine are 30tables/boxes. Calculated by taking 1tablets per day, one box can last for one month. For patients who take medications for a long time, medical insurance reimbursement significantly reduces the financial burden and improves the accessibility of medications.

In addition to domestic purchase channels, some patients will also choose to obtain afatinib through overseas purchase, especially when the medical insurance reimbursement process is cumbersome, drug supply is tight, or medical insurance does not fully cover it. Afatinib on the foreign market is divided into two categories: original drugs and generic drugs. Among them, the Indian original version of afatinib is priced at about more than 5,000 yuan, and its efficacy is the same as the domestic original version. The lower-priced generic drugs come from India, Bangladesh, Laos and other places. Each box usually sells for between a few hundred to more than 2,000 yuan, and is favored by many patients with limited financial conditions.

In general, afatinib already has a relatively mature purchase and medical insurance reimbursement system in China, and most patients can obtain a stable supply of the drug through hospitals. For patients who need to save costs or cannot obtain the medical insurance version in time, overseas generic drugs are also a viable alternative. However, no matter which channel you choose to purchase, afatinib should be taken under the guidance of a professional doctor to ensure the safety and efficacy of the treatment.

References：https://www.giotrif.com/